PsiOxus Therapeutics Limited Completes Patient Enrollment for Phase II Wasting Disease Therapeutic MT-102
3/4/2013 10:30:04 AM
OXFORD, England--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia. The agent’s unique dual mode of action, which has both anti-catabolic and pro-anabolic activity, directly impacts two of the principle pathophysiological hallmarks of cachexia and has been shown to have beneficial effects upon both cachexia and age-related sarcopenia in vivo.
comments powered by